Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab as Single Agent or in Combination in Advanced Solid Tumors
NCT03526835Phase 2Recruiting
- Sponsor
- Genmab
- Start
- May 2018
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of petosemtamab in solid tumor, colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Genmab. Started May 2018; status: recruiting.
02
Drugs
petosemtamab
03
Conditions
solid tumorcolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03526835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526835.